We then aimed to investigate the prognostic value of COMP expression levels in CRC tumors corrected for PD-L1 expression by immune cells and cancer cells, and the different markers of immune cells populations (CD3+, CD8+, FoxP3+, CD68+, CD56+, and CD163+). The gene discussed is COMP; the disease is colorectal carcinoma.